Hyperliquid's IPOP Proposal: A Forensic Look at the Pre-IPO Perpetual Market

The data is the hook. Over five completed IPOP markets on Hyperliquid, the eventual IPO price was consistently 10.8% to 38.4% lower than the pre-listing IPOP market price. That is not a gentle discount. That is a structural anomaly. The Hyperliquid Policy Center (HPC) and trade[XYZ] submitted a joint letter to the SEC on August 19, using this data to argue that their product—Initial Pre-IPO Perpetuals—improves price discovery for public offerings. They claim the IPO process is broken, and their synthetic market provides a more accurate signal. But the ledger bleeds where code is silent. The data comes from the proposers. There is no independent audit. No third-party verification. As a quant who has spent years building and auditing trading systems, I have learned one rule: when the party pitching the solution also provides the proof, skepticism is the only viable alpha. IPOPs are synthetic perpetual contracts tied to a company before its IPO. They allow long and short positions, but confer no equity, no voting rights, no allocation privileges. The contract terminates automatically when the underlying stock begins trading on a public exchange. The settlement price—presumably the IPO price or first trade price—closes the contract. The product is not new in its technical architecture. It is a standard perpetual swap with a custom termination event. The innovation is in the application: using a DEX for pre-IPO price discovery. Hyperliquid has run five such markets, all of which completed their lifecycles. The letter to the SEC proposes a regulatory framework covering classification, disclosure, listing standards, market integrity, and investor access. The stated goal is to bring this product under a clear legal umbrella, rather than operating in the gray zone. Let me dissect the core claim. The letter argues that IPOPs provide a more accurate price discovery mechanism than the traditional IPO book-building process. The evidence: in all five cases, the IPOP market price one day before the IPO was significantly higher than the actual IPO price. This, they argue, shows that underwriters systematically underprice IPOs, leaving money on the table. The IPOP market, by contrast, reflects true demand. That narrative is compelling. But it is also incomplete. Five data points is a small sample. The data is self-reported. The settlement mechanism is undisclosed. I have audited trading protocols where the settlement oracle was a single party's API. That is not a price discovery mechanism; it is a price acceptance mechanism. If the IPOP settlement price is based on the official IPO price, then the product is essentially a highly leveraged bet on a single number that is determined by a small group of Wall Street bankers. The fact that the market trades at a premium could simply be speculation—a pure bet that the IPO price will be low, not a reflection of fair value. The letter presents this as a public good, but the structural risk is that the product amplifies noise, not signal. The order flow analysis reveals a deeper issue: who is providing liquidity on these IPOP markets? trade[XYZ] is likely the primary market maker. They collect the spread. They also have the strongest incentive to see the product succeed. The letter is a lobbying document, not an independent research paper. The contrarian angle is uncomfortable but necessary. The market narrative around this event is that it is a bullish signal for Hyperliquid's ecosystem and for crypto derivatives in general. The institutionalization of pre-IPO trading could bring new capital and legitimacy. But I see a different risk vector. The SEC is not known for embracing unregistered derivatives that reference underlying securities. The Howey test analysis shows medium-high risk: money invested, expectation of profit, and a reliance on the efforts of others—specifically, the market maker and the platform. The letter is a preemptive move to shape regulation before the SEC acts. But the SEC may interpret the data differently. The consistent discount could be seen as evidence that the IPOP market is overpriced, not that the IPO market is underpriced. If the SEC investigates, they will ask: who traded on these markets? Did any traders have non-public information about the IPO timing or pricing? The asymmetry of information in pre-IPO markets is extreme. Insider trading risk is not a theoretical concern; it is a structural feature. The real value of the IPOP product is not in its price discovery, but in its ability to generate fees for the platform and its market makers. Survival is the ultimate performance metric, and for this product to survive, it needs more than a letter. It needs a clear regulatory path that addresses settlement integrity, investor protection, and market manipulation. Looking forward, the takeaway is not about price targets. It is about the information gap. The data presented by HPC and trade[XYZ] is interesting but insufficient. If the SEC responds positively, this could open a new asset class for crypto derivatives. If the SEC remains silent or issues a negative signal, the product will likely retreat to offshore jurisdictions. The prudent stance is to treat the data as a hypothesis, not a conclusion. The market is pricing in a favorable outcome, but the structural risks are understated. The ledger bleeds where code is silent. Apply the same forensic rigor to this data as you would to a suspicious smart contract. Verify the settlement mechanism. Audit the oracle. And wait for the SEC's reply before allocating capital. Skepticism is not a bias. It is a survival trait.